175 related articles for article (PubMed ID: 33899342)
21. The hypervariable region of K-Ras4B is responsible for its specific interactions with calmodulin.
Abraham SJ; Nolet RP; Calvert RJ; Anderson LM; Gaponenko V
Biochemistry; 2009 Aug; 48(32):7575-83. PubMed ID: 19583261
[TBL] [Abstract][Full Text] [Related]
22. Novel membrane-targeted ERK1 and ERK2 chimeras which act as dominant negative, isotype-specific mitogen-activated protein kinase inhibitors of Ras-Raf-mediated transcriptional activation of c-fos in NIH 3T3 cells.
Hochholdinger F; Baier G; Nogalo A; Bauer B; Grunicke HH; Uberall F
Mol Cell Biol; 1999 Dec; 19(12):8052-65. PubMed ID: 10567531
[TBL] [Abstract][Full Text] [Related]
23. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
[TBL] [Abstract][Full Text] [Related]
24. Astrocyte elevated gene-1 (AEG-1) is a target gene of oncogenic Ha-ras requiring phosphatidylinositol 3-kinase and c-Myc.
Lee SG; Su ZZ; Emdad L; Sarkar D; Fisher PB
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17390-5. PubMed ID: 17088530
[TBL] [Abstract][Full Text] [Related]
25. Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways.
Grana TM; Rusyn EV; Zhou H; Sartor CI; Cox AD
Cancer Res; 2002 Jul; 62(14):4142-50. PubMed ID: 12124353
[TBL] [Abstract][Full Text] [Related]
26. Novel tricyclic inhibitors of farnesyl protein transferase. Biochemical characterization and inhibition of Ras modification in transfected Cos cells.
Bishop WR; Bond R; Petrin J; Wang L; Patton R; Doll R; Njoroge G; Catino J; Schwartz J; Windsor W
J Biol Chem; 1995 Dec; 270(51):30611-8. PubMed ID: 8530497
[TBL] [Abstract][Full Text] [Related]
27. It takes two to tango: Dual inhibition of PI3K and MAPK in rhabdomyosarcoma.
Jahangiri A; Weiss WA
Clin Cancer Res; 2013 Nov; 19(21):5811-3. PubMed ID: 24097859
[TBL] [Abstract][Full Text] [Related]
28. Role of phosphoinositide 3-kinase and endocytosis in nerve growth factor-induced extracellular signal-regulated kinase activation via Ras and Rap1.
York RD; Molliver DC; Grewal SS; Stenberg PE; McCleskey EW; Stork PJ
Mol Cell Biol; 2000 Nov; 20(21):8069-83. PubMed ID: 11027277
[TBL] [Abstract][Full Text] [Related]
29. Membrane targeting of the nucleotide exchange factor Sos is sufficient for activating the Ras signaling pathway.
Aronheim A; Engelberg D; Li N; al-Alawi N; Schlessinger J; Karin M
Cell; 1994 Sep; 78(6):949-61. PubMed ID: 7923364
[TBL] [Abstract][Full Text] [Related]
30. Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.
Yuen HF; Abramczyk O; Montgomery G; Chan KK; Huang YH; Sasazuki T; Shirasawa S; Gopesh S; Chan KW; Fennell D; Janne P; El-Tanani M; Murray JT
Biosci Rep; 2012 Aug; 32(4):413-22. PubMed ID: 22668349
[TBL] [Abstract][Full Text] [Related]
31. NMR in integrated biophysical drug discovery for RAS: past, present, and future.
Marshall CB; KleinJan F; Gebregiworgis T; Lee KY; Fang Z; Eves BJ; Liu NF; Gasmi-Seabrook GMC; Enomoto M; Ikura M
J Biomol NMR; 2020 Nov; 74(10-11):531-554. PubMed ID: 32804298
[TBL] [Abstract][Full Text] [Related]
32. Platelet-derived growth factor receptor mediates activation of ras through different signaling pathways in different cell types.
Satoh T; Fantl WJ; Escobedo JA; Williams LT; Kaziro Y
Mol Cell Biol; 1993 Jun; 13(6):3706-13. PubMed ID: 8388543
[TBL] [Abstract][Full Text] [Related]
33. Induction of oocyte maturation by jun-N-terminal kinase (JNK) on the oncogenic ras-p21 pathway is dependent on the raf-MEK signal transduction pathway.
Chie L; Amar S; Kung HF; Lin MC; Chen H; Chung DL; Adler V; Ronai Z; Friedman FK; Robinson RC; Kovac C; Brandt-Rauf PW; Yamaizumi Z; Michl J; Pincus MR
Cancer Chemother Pharmacol; 2000; 45(6):441-9. PubMed ID: 10854130
[TBL] [Abstract][Full Text] [Related]
34. Molecular mechanism of activation of class IA phosphoinositide 3-kinases (PI3Ks) by membrane-localized HRas.
Siempelkamp BD; Rathinaswamy MK; Jenkins ML; Burke JE
J Biol Chem; 2017 Jul; 292(29):12256-12266. PubMed ID: 28515318
[TBL] [Abstract][Full Text] [Related]
35. The P34G mutation reduces the transforming activity of K-Ras and N-Ras in NIH 3T3 cells but not of H-Ras.
Oliva JL; Zarich N; Martínez N; Jorge R; Castrillo A; Azañedo M; García-Vargas S; Gutiérrez-Eisman S; Juarranz A; Boscá L; Gutkind JS; Rojas JM
J Biol Chem; 2004 Aug; 279(32):33480-91. PubMed ID: 15181015
[TBL] [Abstract][Full Text] [Related]
36. The Hypervariable Region of K-Ras4B Governs Molecular Recognition and Function.
Abdelkarim H; Banerjee A; Grudzien P; Leschinsky N; Abushaer M; Gaponenko V
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31739603
[TBL] [Abstract][Full Text] [Related]
37. Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers.
Nussinov R; Zhang M; Tsai CJ; Jang H
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2304-2314. PubMed ID: 29097261
[TBL] [Abstract][Full Text] [Related]
38. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor.
Lerner EC; Qian Y; Hamilton AD; Sebti SM
J Biol Chem; 1995 Nov; 270(45):26770-3. PubMed ID: 7592913
[TBL] [Abstract][Full Text] [Related]
39. Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma.
Takai M; Nakagawa T; Tanabe A; Terai Y; Ohmichi M; Asahi M
Cancer Biol Ther; 2015; 16(2):325-35. PubMed ID: 25756515
[TBL] [Abstract][Full Text] [Related]
40. R-Ras3, a brain-specific Ras-related protein, activates Akt and promotes cell survival in PC12 cells.
Kimmelman AC; Osada M; Chan AM
Oncogene; 2000 Apr; 19(16):2014-22. PubMed ID: 10803462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
